Coherus Biosciences | CHRS - Gross Profit On Sales


Coherus Biosciences reported $8.7M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.89B 415M Dec/2025
Baxter International USD 891M 314M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Fujifilm JPY 376.67B 29.16B Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Merck USD 10.85B 2.57B Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xencor USD 21M 22.61M Sep/2025
Zoetis USD 1.62B 20M Mar/2026